Marie Jose Guillen Navarro

5PUBLICATIONS
42CO-AUTHORS
Biologically active moleculesMolecular targetsPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 14, 2026
Antitumor activity of novel transcriptional inhibitors ecubectedin and PM54 in soft tissue sarcoma patient-derived xenografts.

|Jan 02, 2026
PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity.

Pablo Aviles, Marcelo Lima Ribeiro, Maria Jose Guillén

|Jan 08, 2025
Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity.

Max Cigrang, Julian Obid, Maguelone Nogaret

|Dec 05, 2024
Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.

Antonio Calles, Emiliano Calvo, Gema Santamaría Nuñez

|Aug 28, 2024
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models.

F Pantano, S Simonetti, M Iuliani

Pageof 1

Frequent Collaborators

3 joint publications

Gema Santamaria-Nuñez

3 joint publications

Pablo Aviles

2 joint publications

Marta Martinez-Diez

2 joint publications

Carmen Cuevas